Enhancement of solubility, dissolution rate and bioavailability of atorvastatin using solid lipid: in vitro and in vivo characterization

다국어 초록 (Multilingual Abstract)

The objective of present investigation was to enhance solubility, dissolution rate and bioavailability of poorly water soluble drug atorvastatin using solid lipid glycerol monostearate and surfactant poloxamer-407. Oral pastilles of glycerol monostearate and poloxamer were formulated by pastillation technique and optimized by central composite design. Hemispherical pastilles were evaluated for drug content, saturation solubility study, thermal properties and in vitro, ex vivo and in vivo drug release study. Formulation F4 at high level of glycerol monostearate (1000 mg) and poloxamer-407 (400 mg) showed 25-fold and 3-fold increased in solubility and dissolution rate, respectively. X-Ray diffraction and scanning electron microscopic study proved the decrease in crystallinity of atorvastatin and confirmed the conversion of crystalline to amorphous form, respectively. Ex vivo study revealed that maximum amount of released drug was absorbed through the everted intestine. In vivo study in rats showed higher HMG CoA to mevalonate ratio of pastilles than plain drug. This indicated better bioavailability and hyperlipidemic activity of pastilles than atorvastatin. Thus, the solubility, dissolution rate and bioavailability of atorvastatin were enhanced successfully using lipid carrier system.

참고문헌 (Reference)

1 Cespi M, "Stress relaxation test for the characterization of the viscoelasticity of pellets" 67 : 476-484, 2007

2 Ibric S, "Solubility enhancement of desloratadine by solid dispersion in poloxamers" 436 : 161-170, 2012

3 Eloy J, "Solid dispersions containing ursolic acid in Poloxamer 407 and PEG 6000 : a comparative study of fusion and solvent methods" 253 : 98-106, 2014

4 Partani P, "Simultaneous equation of atorvastatin and its two active metabolites in human plasma by liquid chromatography/electrospray tandem mass spectrometry" 4 (4): 26-36, 2014

5 Kim M, "Preparation, characterization and in vivo evaluation of amorphous atorvastatin calcium nano particles using supercritical antisolvent, (SAS), process" 69 : 454-465, 2008

6 Kim J, "Prediction of degree of deformation and crystallization time of molten droplets in pastillation process" 257 : 205-215, 2003

7 Kalepu S, "Oral lipidbased drug delivery systems—an overview" 3 (3): 361-372, 2013

8 Ashlesha P. Pandit, "Oral lipid based multiparticulate pastilles: design and effect of pore former" 한국약제학회 45 (45): 23-33, 2015

9 Prabhu S, "Novel lipid-based formulations enhancing the in vitro dissolution and permeability characteristics of a poorly water-soluble model drug piroxicam" 301 : 209-216, 2005

10 Chakraborty S, "Lipid—an emerging platform for oral delivery of drugs with poor bioavailability" 73 : 1-15, 2009

11 Venugopal Rao A, "Indirect assessment of hydroxymethylglutaryl-CoA reductase, (NADPH), activity in liver tissue" 21 : 1523-1525, 1975

12 Porter CJ, "In vitro assessment of oral lipid based formulations" 50 : 127-147, 2001

13 Pankaj G. Jain, "Hypolipidemic activity of Moringa oleifera Lam., Moringaceae, on high fat diet induced hyperlipidemia in albino rats" Elsevier BV 20 (20): 969-973, 2010

14 Pushp RN, "Enhancement of solubility and dissolution of Coenzyme Q10 using solid dispersion formulation" 383 : 147-153, 2010

15 Anwar M, "Enhanced bioavailability of nano-sized chitosan–atorvastatin conjugate after oral administration to rats" 44 : 241-249, 2011

16 Kleinebudde P, "Dissolution of solid lipid extrudates in biorelevant media" 422 : 116-124, 2012

17 Zakir F, "Development and characterization of an atorvastatin solid dispersion formulation using skimmed milk for improved oral bioavailability" 2 : 421-428, 2012

18 Pandit AP, "An apparatus for conducting ex vivo studies on tissues"